MAO-A and MAO-B Variants: Neurotransmitter Breakdown and Dysautonomia

Monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) are enzymes that break down monoamine neurotransmitters — serotonin, dopamine, norepinephrine, and epinephrine — through oxidative deamination. Variants in these genes can significantly alter neurotransmitter levels, with direct implications for dysautonomia, MCAS, anxiety, and treatment responses. Understanding MAO variants is particularly relevant for patients who are considering or currently taking SNRIs, SSRIs, or MAO inhibitors.

MAO-A vs. MAO-B: Different Substrates, Different Locations

MAO-A and MAO-B have overlapping but distinct substrate preferences:

MAO-A is the primary enzyme for serotonin and norepinephrine degradation, making it particularly relevant for dysautonomia patients. MAO-B is more important for dopamine metabolism in the brain.

Key MAO-A Variants

The MAO-A gene is located on the X chromosome, which means males have only one copy (hemizygous) while females have two copies. This has important implications for how variants affect enzyme activity:

MAOA-uVNTR (upstream variable number tandem repeat): This is the most studied MAO-A variant. The promoter region contains a 30-base pair repeat sequence that comes in 2, 3, 3.5, 4, or 5 repeat copies. The 3-repeat and 5-repeat alleles are associated with higher MAO-A transcription (high-activity), while the 3.5-repeat and 4-repeat alleles are associated with lower transcription (low-activity).

Low-activity MAO-A variants are associated with:

• Higher baseline serotonin and norepinephrine levels
• Greater stress reactivity and anxiety
• Increased sensitivity to serotonergic medications
• Potentially higher risk of serotonin syndrome with serotonergic drugs

High-activity MAO-A variants are associated with:

• Lower baseline serotonin levels
• Potentially greater vulnerability to depression
• Better tolerance of serotonergic medications

MAO-A and Dysautonomia

The connection between MAO-A variants and dysautonomia runs through norepinephrine metabolism. In hyperadrenergic POTS, elevated circulating norepinephrine is a defining feature. MAO-A is one of the primary enzymes responsible for degrading norepinephrine in peripheral tissues. Low-activity MAO-A variants may contribute to elevated norepinephrine by slowing its degradation.

This is mechanistically similar to the COMT connection — both COMT and MAO-A degrade norepinephrine, and variants in either gene can contribute to catecholamine accumulation. Patients with both low-activity COMT and low-activity MAO-A variants may have a significantly elevated norepinephrine burden.

MAO-A and MCAS

MAO-A also degrades histamine in the gut and liver, making it relevant for MCAS and histamine intolerance. Low-activity MAO-A variants may impair histamine degradation, contributing to histamine accumulation — particularly relevant for patients who already have DAO or HNMT variants.

Treatment Implications

SNRI and SSRI sensitivity. Patients with low-activity MAO-A variants may be more sensitive to serotonergic medications (SSRIs, SNRIs) and at higher risk of serotonin syndrome, particularly when combining multiple serotonergic agents. Starting at lower doses and titrating slowly is advisable.

MAO inhibitors. MAO inhibitors (phenelzine, tranylcypromine, selegiline) are used for depression and Parkinson's disease. Patients with low-activity MAO-A variants may have exaggerated responses to MAO inhibitors and are at higher risk of hypertensive crisis with tyramine-containing foods.

Riboflavin (B2). MAO enzymes require riboflavin (FAD) as a cofactor. Riboflavin deficiency can reduce MAO activity, potentially worsening catecholamine accumulation. Ensuring adequate B2 intake is a simple, low-risk intervention.

Avoiding tyramine-rich foods. For patients with low-activity MAO-A variants, reducing dietary tyramine (aged cheeses, cured meats, fermented foods, red wine) may reduce the catecholamine burden, as tyramine is a substrate for MAO-A that can displace norepinephrine from storage vesicles.

Key Takeaways

MAO-A and MAO-B variants are clinically relevant for dysautonomia patients, particularly those with hyperadrenergic POTS, MCAS, and significant anxiety. Low-activity MAO-A variants can contribute to elevated norepinephrine and histamine levels and increase sensitivity to serotonergic medications. Understanding your MAO status can inform medication choices, dietary modifications, and supplement selection.

This article is for informational purposes only and does not constitute medical advice.